The World Health Organisation (WHO) has begun expanding its scientific collaboration and monitoring of emerging variants of SARS-CoV-2, the virus that causes COVID-19. WHO, in a statement posted on its website, stated the agency had met with scientists globally to discuss critical knowledge gaps and research priorities for emerging variants of the virus.
WHO convened a daylong virtual meeting of scientists from around the globe, which brought together over 1,750 experts from 124 countries to discuss emerging variants of the virus. WHO Director-General, Dr. Tedros Ghebreyesus, said: “Science and research have played a vital role in responding to the pandemic since day one and will continue to be the heartbeat of everything WHO does.”
The consultation was structured around six thematic areas covering epidemiology and mathematical modelling, evolutionary biology, animal models, assays and diagnostics, clinical management and therapeutics and vaccines, the statement said. “Scientists noted the importance of research to detect and understand early on the potential impact of emerging variants on diagnostics, treatments and vaccines.
“There was a consensus on the importance of integrating the new SARSCoV- 2 variants research into the global research and innovation agenda, while enhancing coordination across disciplines,” Ghebreyesus said. Dr. Ana Henao Restrepo, Head of WHO’s Research and Development Blueprint, said: “Our collective goal is to get ahead of the game. It is our goal to get ahead of the game and have a global mechanism to quickly identify and study variants of concern and understand their implications for disease control efforts.” She noted that it was normal for viruses to mutate, but the more the SARS-CoV-2 virus spreads, the more opportunities it has to change.
High levels of transmission mean that we should expect more variants to emerge, she said. “Of the significant variants reported so far, some are associated with increases in transmissibility, but not disease severity. Research is on-going to address whether the changes impact public health tools and measures. “Genomic sequencing has been critical in identifying and responding to new variants,” she said. Similarly, Dr. Maria Van Kerkhove, WHO Technical Lead on COVID-19, said: “So far, an astounding 350,000 sequences have been publicly shared, but most come from just a handful of countries.
“Improving the geographic coverage of sequencing is critical for the world to have eyes and ears on changes to the virus.” Accordingly, WHO said increasing sequencing capacity across the world be one of its priority research area. “Better surveillance and laboratory capacity to monitor strains of concern needs to be accompanied by prompt sharing of virus and serum samples via globally agreed mechanisms so that critical research can be promptly initiated each time.
“Scientists highlighted the importance of national data platforms to document critical clinical, epidemiological and virus data that facilitates the detection and assessment of new SARS-CoV-2 variants,” it stated.